ACS Central ScienceMicrobiologyPeer-reviewed journal article
Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir
H. S. Lo, K. P. Y. Hui, H.-M. Lai, K. S. Khan, S. Kaur, J. Huang, Z. Li, A. K. N. Chan, H. H.-Y. Cheung, K. C. Ng, J. C. W. Ho, Y. W. Chen, B. Ma, P. M.-H. Cheung, D. Shin, K. Wang, M.-H. Lee, B. Selisko, C. Eydoux, J.-C. Guillemot, B. Canard, K.-P. Wu, I. Dikic, P.-H. Liang, Z. Zuo, , W.-L. Ng
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global threat to human health. Using a multidisciplinary approach, we identified and validated the hepatitis C virus (HCV) protease inhibitor simeprevir as an especially promising repurposable drug for treating COVID-19. Simeprevir potently reduces SARS-CoV-2 viral load by multiple orders of magnitude and synergizes with remdesivir in vitro. Mechanistically, we showed that simeprevir inhibits the main protease (Mpro) and unexpectedly the RNA-dependent RNA polymerase (RdRp). Our results thus reveal the viral protein targets of simeprevir, and provide preclinical rationale for the combination of simeprevir and remdesivir for the pharmacological management of COVID-19 patients. One Sentence SummaryDiscovery of simeprevir as a potent suppressor of SARS-CoV-2 viral replication that synergizes with remdesivir.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture
K. Bafna, K. White, … G. T. Montelione·bioRxiv·Dec 13, 2020
- Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
X. Nguyenla, E. Wehri, … J. Schaletzky·bioRxiv·Sep 18, 2020
- Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro
K. A. Gammeltoft, Y. Zhou, … J. M. Gottwein·bioRxiv·Dec 2, 2020
- Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
L. Jeffreys, S. H. Pennington, … G. A. Biagini·bioRxiv·Dec 23, 2020
- The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication
Doha Al Krad, Kim M. Stegmann, … Matthias Dobbelstein·Antiviral ResearchPeer-reviewed·Jul 29, 2025
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication
I. L. Shytaj, M. Fares, … M. Lusic·bioRxiv·Mar 9, 2021